Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy

N. Raben, N. Lu, K. Nagaraju, Y. Rivera, A. Lee, B. Yan, B. Byrne, P. J. Meikle, K. Umapathysivam, J. J. Hopwood, P. H. Plotz

Research output: Contribution to journalArticle

Abstract

Both enzyme replacement and gene therapy of lysosomal storage disorders rely on the receptor-mediated uptake of lysosomal enzymes secreted by cells, and for each lysosomal disorder it is necessary to select the correct cell type for recombinant enzyme production or for targeting gene therapy. For example, for the therapy of Pompe disease, a severe metabolic myopathy and cardiomyopathy caused by deficiency of acid α-glucosidase (GAA), skeletal muscle seems an obvious choice as a depot organ for local therapy and for the delivery of the recombinant enzyme into the systemic circulation. Using knockout mice with this disease and transgenes containing cDNA for the human enzyme under muscle or liver specific promoters controlled by tetracycline, we have demonstrated that the liver provided enzyme far more efficiently. The achievement of therapeutic levels with skeletal muscle transduction required the entire muscle mass to produce high levels of enzyme of which little found its way to the plasma, whereas liver, comprising

Original languageEnglish (US)
Pages (from-to)2039-2047
Number of pages9
JournalHuman Molecular Genetics
Volume10
Issue number19
StatePublished - 2001
Externally publishedYes

Fingerprint

Glucosidases
Knockout Mice
Acids
Enzymes
Genes
Genetic Therapy
Liver
Skeletal Muscle
Therapeutics
Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Muscles
Muscular Diseases
Tetracycline
Transgenes
Cardiomyopathies
Complementary DNA

ASJC Scopus subject areas

  • Genetics

Cite this

Raben, N., Lu, N., Nagaraju, K., Rivera, Y., Lee, A., Yan, B., ... Plotz, P. H. (2001). Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy. Human Molecular Genetics, 10(19), 2039-2047.

Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice : Implications for therapy. / Raben, N.; Lu, N.; Nagaraju, K.; Rivera, Y.; Lee, A.; Yan, B.; Byrne, B.; Meikle, P. J.; Umapathysivam, K.; Hopwood, J. J.; Plotz, P. H.

In: Human Molecular Genetics, Vol. 10, No. 19, 2001, p. 2039-2047.

Research output: Contribution to journalArticle

Raben, N, Lu, N, Nagaraju, K, Rivera, Y, Lee, A, Yan, B, Byrne, B, Meikle, PJ, Umapathysivam, K, Hopwood, JJ & Plotz, PH 2001, 'Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy', Human Molecular Genetics, vol. 10, no. 19, pp. 2039-2047.
Raben, N. ; Lu, N. ; Nagaraju, K. ; Rivera, Y. ; Lee, A. ; Yan, B. ; Byrne, B. ; Meikle, P. J. ; Umapathysivam, K. ; Hopwood, J. J. ; Plotz, P. H. / Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice : Implications for therapy. In: Human Molecular Genetics. 2001 ; Vol. 10, No. 19. pp. 2039-2047.
@article{be6f8c608ada42008318d2c77e6c4328,
title = "Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy",
abstract = "Both enzyme replacement and gene therapy of lysosomal storage disorders rely on the receptor-mediated uptake of lysosomal enzymes secreted by cells, and for each lysosomal disorder it is necessary to select the correct cell type for recombinant enzyme production or for targeting gene therapy. For example, for the therapy of Pompe disease, a severe metabolic myopathy and cardiomyopathy caused by deficiency of acid α-glucosidase (GAA), skeletal muscle seems an obvious choice as a depot organ for local therapy and for the delivery of the recombinant enzyme into the systemic circulation. Using knockout mice with this disease and transgenes containing cDNA for the human enzyme under muscle or liver specific promoters controlled by tetracycline, we have demonstrated that the liver provided enzyme far more efficiently. The achievement of therapeutic levels with skeletal muscle transduction required the entire muscle mass to produce high levels of enzyme of which little found its way to the plasma, whereas liver, comprising",
author = "N. Raben and N. Lu and K. Nagaraju and Y. Rivera and A. Lee and B. Yan and B. Byrne and Meikle, {P. J.} and K. Umapathysivam and Hopwood, {J. J.} and Plotz, {P. H.}",
year = "2001",
language = "English (US)",
volume = "10",
pages = "2039--2047",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "19",

}

TY - JOUR

T1 - Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice

T2 - Implications for therapy

AU - Raben, N.

AU - Lu, N.

AU - Nagaraju, K.

AU - Rivera, Y.

AU - Lee, A.

AU - Yan, B.

AU - Byrne, B.

AU - Meikle, P. J.

AU - Umapathysivam, K.

AU - Hopwood, J. J.

AU - Plotz, P. H.

PY - 2001

Y1 - 2001

N2 - Both enzyme replacement and gene therapy of lysosomal storage disorders rely on the receptor-mediated uptake of lysosomal enzymes secreted by cells, and for each lysosomal disorder it is necessary to select the correct cell type for recombinant enzyme production or for targeting gene therapy. For example, for the therapy of Pompe disease, a severe metabolic myopathy and cardiomyopathy caused by deficiency of acid α-glucosidase (GAA), skeletal muscle seems an obvious choice as a depot organ for local therapy and for the delivery of the recombinant enzyme into the systemic circulation. Using knockout mice with this disease and transgenes containing cDNA for the human enzyme under muscle or liver specific promoters controlled by tetracycline, we have demonstrated that the liver provided enzyme far more efficiently. The achievement of therapeutic levels with skeletal muscle transduction required the entire muscle mass to produce high levels of enzyme of which little found its way to the plasma, whereas liver, comprising

AB - Both enzyme replacement and gene therapy of lysosomal storage disorders rely on the receptor-mediated uptake of lysosomal enzymes secreted by cells, and for each lysosomal disorder it is necessary to select the correct cell type for recombinant enzyme production or for targeting gene therapy. For example, for the therapy of Pompe disease, a severe metabolic myopathy and cardiomyopathy caused by deficiency of acid α-glucosidase (GAA), skeletal muscle seems an obvious choice as a depot organ for local therapy and for the delivery of the recombinant enzyme into the systemic circulation. Using knockout mice with this disease and transgenes containing cDNA for the human enzyme under muscle or liver specific promoters controlled by tetracycline, we have demonstrated that the liver provided enzyme far more efficiently. The achievement of therapeutic levels with skeletal muscle transduction required the entire muscle mass to produce high levels of enzyme of which little found its way to the plasma, whereas liver, comprising

UR - http://www.scopus.com/inward/record.url?scp=0034772350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034772350&partnerID=8YFLogxK

M3 - Article

C2 - 11590121

AN - SCOPUS:0034772350

VL - 10

SP - 2039

EP - 2047

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 19

ER -